公开(公告)号：US09487571B2

公开(公告)日：2016-11-08

申请号：US14026671

申请日：2013-09-13

Applicant: Indiana University Research and Technology Corporation

Inventor： Richard D. DiMarchi ,  Tao Ma

IPC: A61K38/26 ,  A61K38/00 ,  C07K14/605

CPC classification number: C07K14/605 ,  A61K38/26 ,  A61K2300/00

Abstract: Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Method of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.

Abstract translation: 本文提供了包含GIP激动剂肽和胰高血糖素拮抗肽的肽组合。 在一些实施方案中，肽组合作为组合物例如药物组合物提供，而在其它实施方案中，肽组合作为试剂盒提供。 在其它实施方案中，肽组合作为缀合物提供，例如融合肽，异二聚体。 在具体方面，GIP激动剂肽是天然人胰高血糖素的类似物。 在具体方面，胰高血糖素拮抗剂肽是天然人胰高血糖素的类似物。 在一些实施方案中，GIP激动剂肽通过接头共价连接到胰高血糖素拮抗剂肽。 进一步提供治疗疾病例如代谢紊乱（例如糖尿病和肥胖症）的方法，其包括施用本文所述的肽组合物。

公开(公告)号：US09790263B2

公开(公告)日：2017-10-17

申请号：US14840580

申请日：2015-08-31

Applicant: Indiana University Research and Technology Corporation

Inventor： Richard D. DiMarchi ,  Tao Ma

IPC: A61K38/26 ,  C07K14/605 ,  C07K7/00 ,  A61K38/00

CPC classification number: C07K14/605 ,  A61K38/00 ,  A61K38/26

Abstract: Glucagon peptides with increased GIP activity are provided, optionally with GLP-1 and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.